Analysis of primary-refractory Hodgkin lymphoma pts in a randomized, placebo-controlled study of brentuximab vedotin consolidation after autologous stem cell transplant.
Analysis of primary-refractory Hodgkin lymphoma pts in a randomized, placebo-controlled study of brentuximab vedotin consolidation after autologous stem cell transplant.
Clin Adv Hematol Oncol. 2015 Aug;13(8 Suppl 9):14-5
Authors: Moskowitz CH
PMID: 26452084 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
More News: Cancer & Oncology | Hematology | Lymphoma | Stem Cell Therapy | Stem Cells | Study | Transplants